Albrecht J, Mempel M, Hein R, Abeck D, Ring J
Klinik und Poliklinik für Dermatologie und Allergologie am Biederstein, Technische Universität München.
Hautarzt. 1999 Nov;50(11):809-11. doi: 10.1007/s001050050989.
A 26-year old patient who suffered from purpura for four years evolved into the complete clinical picture of Henoch-Schönlein-purpura in the past two years. A causative agent was never found. Multiple therapeutic approaches including systemic steroids, azathioprine as well as pentoxyfylline failed to control the arthralgias, intestinal symptoms and skin lesions. Therefore dapsone therapy was initiated at a dosage of 100 mg daily after checking the glucose-6-phosphate-dehydrogenase and with regular control of the blood methemoglobin level. Within two weeks, the patient's symptoms completely cleared, he has now been in remission for the past six months. As noted elsewhere, dapsone is an effective therapy for severe cases of Henoch-Schönlein- purpura.
一名患有紫癜四年的26岁患者在过去两年中发展为典型的过敏性紫癜临床表现。从未找到致病因素。包括全身用类固醇、硫唑嘌呤以及己酮可可碱在内的多种治疗方法均未能控制关节痛、肠道症状和皮肤病变。因此,在检查葡萄糖-6-磷酸脱氢酶并定期监测血液高铁血红蛋白水平后,开始使用氨苯砜治疗,剂量为每日100毫克。两周内,患者症状完全消失,目前已缓解六个月。如其他地方所指出的,氨苯砜是治疗重症过敏性紫癜的有效疗法。